bluebird bio マネジメント

マネジメント基準チェック /24

bluebird bioの CEO はAndrew Obenshainで、 Jan2021年に任命され、の在任期間は 3.83年です。の年間総報酬は$ 3.05Mで、 22.4%給与と77.6%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.048%を直接所有しており、その価値は€ 33.14K 。経営陣と取締役会の平均在任期間はそれぞれ2.3年と13.7年です。

主要情報

Andrew Obenshain

最高経営責任者

US$3.0m

報酬総額

CEO給与比率	22.4%
CEO在任期間	3.8yrs
CEOの所有権	0.05%
経営陣の平均在職期間	2.3yrs
取締役会の平均在任期間	13.7yrs

経営陣の近況

Recent updates

CEO報酬分析

bluebird bio の収益と比較して、Andrew Obenshain の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$293m
Jun 30 2024	n/a	n/a	-US$319m
Mar 31 2024	n/a	n/a	-US$301m
Dec 31 2023	US$3m	US$682k	-US$212m
Sep 30 2023	n/a	n/a	-US$63m
Jun 30 2023	n/a	n/a	-US$52m
Mar 31 2023	n/a	n/a	-US$89m
Dec 31 2022	US$2m	US$643k	-US$230m
Sep 30 2022	n/a	n/a	-US$431m
Jun 30 2022	n/a	n/a	-US$507m
Mar 31 2022	n/a	n/a	-US$563m
Dec 31 2021	US$9m	US$486k	-US$563m

報酬と市場: Andrewの総報酬 ($USD 3.05M ) は、 German市場 ($USD 474.54K ) の同規模の企業の平均を上回っています。

報酬と収益: Andrewの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Andrew Obenshain (50 yo)

3.8yrs

在職期間

US$3,049,181

報酬

Mr. Andrew Obenshain has been the Chief Executive Officer and Director of bluebird bio, Inc. since 2021 and serves as its President. He served as President of Severe Genetic Diseases since October 2020 unt...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Andrew Obenshain	President	3.8yrs	US$3.05m	0.048% € 33.1k
Thomas Klima	Chief Commercial Officer & COO	2.3yrs	US$1.33m	0.087% € 60.0k
Richard Colvin	Chief Medical Officer	3.7yrs	US$1.34m	0.022% € 15.3k
Oliver Sterling	CFO & Principal Accounting Officer	less than a year	データなし	データなし
Joseph Vittiglio	Chief Legal & Business Officer and Secretary	1.8yrs	データなし	0.0037% € 2.6k
Jess Rowlands	Head of Corporate Communications	1.9yrs	データなし	データなし
Andrea Walton	Chief People Officer	2.8yrs	データなし	データなし
Kasra Kasraian	Senior Vice President of Technical Development & Operations	no data	データなし	データなし
Scott Shoemaker	Senior Vice President of Quality	3.8yrs	データなし	データなし
Sarah Alspach	Senior Vice President of External Affairs	1.9yrs	データなし	データなし
Leslie Wilder	VP & Head of Regulatory Science	no data	データなし	データなし
Jessica Whitten	VP & Global Controller	no data	データなし	データなし

2.3yrs

平均在職期間

52yo

平均年齢

経験豊富な経営陣: BLEの経営陣は経験豊富であると考えられます ( 2.3年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Andrew Obenshain	President	3.8yrs	US$3.05m	0.048% € 33.1k
Philip Reilly	Member of Scientific Advisory Board	13.7yrs	データなし	データなし
Philippe Leboulch	Co-Chair of Scientific Advisory Board	no data	データなし	データなし
Stephen Goff	Member of Scientific Advisory Board	13.7yrs	データなし	データなし
Mark Vachon	Independent Chairman	10.3yrs	US$200.91k	0.013% € 8.8k
Mitchell Finer	Member of Scientific Advisory Board	9.3yrs	US$1.57m	データなし
Malcolm Brenner	Member of Scientific Advisory Board	13.7yrs	データなし	データなし
Christof von Kalle	Member of Scientific Advisory Board	13.7yrs	データなし	データなし
John Agwunobi	Independent Director	7.4yrs	US$160.91k	0.014% € 9.3k
Nick Leschly	Director	14.7yrs	US$96.41k	0.23% € 160.7k
R. Humphries	Member of Scientific Advisory Board	13.7yrs	データなし	データなし
Elisabeth Leiderman	Independent Director	3yrs	US$167.91k	0.011% € 7.9k

13.7yrs

平均在職期間

65yo

平均年齢

経験豊富なボード: BLEの取締役会は経験豊富で経験豊富です ( 13.7年の平均在任期間)。

bluebird bio マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

bluebird bio, Inc., Annual General Meeting, Nov 06, 2024

bluebird bio, Inc. Announces Chief Financial Officer Changes, Effective June 10, 2024

President recently sold €54k worth of stock

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Recent updates

New major risk - Negative shareholders equity

Forecast to breakeven in 2026

bluebird bio, Inc. to Present Additional Long-Term Follow-Up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

bluebird bio Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5450(a)(1)

bluebird bio, Inc., Annual General Meeting, Nov 06, 2024

bluebird bio Announces Receipt of Expected Notices from Nasdaq Due to Non-Compliance with Nasdaq Listing Rule 5250(c)(1)

bluebird bio, Inc. Provides Revenue Guidance for the Third and Fourth Quarter of 2024

bluebird bio, Inc. Announces Chief Financial Officer Changes, Effective June 10, 2024

bluebird bio, Inc. announced delayed 10-Q filing

Bluebird Bio, Inc. Announces Completion of First Cell Collection for LYFGENIA Gene Therapy

Bragar Eagel & Squire, P.C. Files Class Action Lawsuit Against Bluebird Bio Inc

bluebird bio, Inc. announced delayed annual 10-K filing

bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

New major risk - Shareholder dilution

bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

bluebird bio, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

New major risk - Revenue and earnings growth

Bluebird Bio Inc. Presents Long-Term Data At Ash Support Beti-Ccel as A Potentially Curative Gene Therapy for -Thalassemia Patients Who Require Regular Transfusion Independence and Normal or Near- Normal- Normal- Normal-Normal Adult Hb Levels

Bluebird Bio Details Plans for the Commercial Launch of Lyfgenia(Tm) Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and A History of Vaso-Occlusive Events

Now 41% undervalued after recent price drop

Bluebird Bio, Inc. Announces FDA Approval of LYFGENIA™? (Lovo-Ccel) for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events

Now 24% undervalued

Third quarter 2023 earnings released: US$0.66 loss per share (vs US$0.94 loss in 3Q 2022)

New major risk - Revenue and earnings growth

Bluebird Bio, Inc. to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology Annual Meeting and Exposition

bluebird bio, Inc. to Report Q3, 2023 Results on Nov 07, 2023

bluebird bio, Inc. to Report Q3, 2023 Results on Nov 07, 2023

New minor risk - Insider selling

President recently sold €54k worth of stock

Second quarter 2023 earnings released: US$0.67 loss per share (vs US$1.36 loss in 2Q 2022)

bluebird bio, Inc. Announces FDA Priority Review of the Biologics License Application for Lovotibeglogene Autotemcel (Lovo-Cel) for Patients with Sickle Cell Disease (Scd) 12 Years and Older with a History of Vaso-Occlusive Events

First quarter 2023 earnings released: EPS: US$0.21 (vs US$1.66 loss in 1Q 2022)

Less than half of directors are independent

Full year 2022 earnings released: US$3.39 loss per share (vs US$8.17 loss in FY 2021)

Less than half of directors are independent

Less than half of directors are independent

bluebird bio, Inc. Appoints Joseph Vittiglio, JD as Chief Business and Legal Officer

U.S. Food and Drug Administration Lifts Partial Clinical Hold for bluebird bio, Inc.’s Sickle Cell Disease Studies for Patients Under the Age of 18

Bluebird Bio, Inc. Presents New and Updated Data At the 64Th American Society of Hematology Annual Meeting and Exposition

An unknown buyer entered into a definitive agreement to acquire SKYSONA & ZYNTEGLO of bluebird bio, Inc. (NasdaqGS:BLUE) for approximately $100 million.

Less than half of directors are independent

Third quarter 2022 earnings released: US$0.94 loss per share (vs US$2.23 loss in 3Q 2021)

bluebird bio, Inc. Appoints Christopher Krawtschuk as Treasurer, Principal Financial Officer and Principal Accounting Officer

bluebird bio, Inc. Announces Executive Changes Effective October 14, 2022

bluebird bio Receives FDA Accelerated Approval for SKYSONA® Gene Therapy for Early, Active Cerebral Adrenoleukodystrophy (CALD)

bluebird bio, Inc. Announces Executive Changes

Treasurer recently sold €78k worth of stock

bluebird bio, Inc. Announces FDA Approval of Zynteglo®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions

President recently sold €94k worth of stock

Second quarter 2022 earnings released: US$1.36 loss per share (vs US$2.31 loss in 2Q 2021)

bluebird bio, Inc. Appoints Tom Klima as Chief Commercial & Operating Officer, Effective August 8, 2022

bluebird bio, Inc. Announces That the U.S. Food and Drug Administration's Cellular, Tissue and Gene Therapies Advisory Committee Recommends Approval of elivaldogene autotemcel (eli-cel) for the Treatment of Early Active Cerebral Adrenoleukodystrophy

FDA Advisory Committee Unanimously Endorses eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy

Less than half of directors are independent

bluebird bio, Inc., Annual General Meeting, Jun 22, 2022

Bluebird Bio, Inc. Announces Executive Changes

bluebird bio, Inc. appoints Charlotte Jones-Burton as Class I director, effective March 7, 2022

bluebird bio, Inc. announced delayed annual 10-K filing

bluebird bio, Inc. Announces Resignation of Jessica Whitten as Chief Accounting Officer and Principal Accounting Officer

CEO & Director recently sold €65k worth of stock

bluebird Provides Update on FDA Review Timelines for Betibeglogene Autotemcel (beti-cel) for Beta-Thalassemia and Elivaldogene Autotemcel (eli-cel) for Cerebral Adrenoleukodystrophy (CALD)

bluebird bio, Inc. to Launch Both beti-cel and eli-cel for Patients in the U.S. in Mid-2022

bluebird bio, Inc. Announces Partial Clinical Hold for Patients Under 18 in Sickle Cell Gene Therapy Clinical Program

bluebird bio Announces FDA Priority Review of Biologics License Application for eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) in Patients Without a Matched Sibling Donor

bluebird bio, Inc. Announces Updated Results from its Phase 1/2 HGB-206 Study of Lovotibeglogene Autotemcel Gene Therapy

New Data At ASH21, Published in Nejm Further Demonstrate Beti-Cel as A Potentially Curative One-Time Gene Therapy for ß-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Ti and Normal or Near-Normal Adult Hb Levels

Bluebird Bio, Inc. Announces FDA Priority Review of Biologics License Application for Beti-Cel Gene Therapy for Patients with ß-Thalassemia Who Require Regular Red Blood Cell Transfusions

Third quarter 2021 earnings released: US$3.16 loss per share (vs US$2.94 loss in 3Q 2020)

Insufficient new directors

マネジメント基準チェック /24